In October this year, Avenue Therapeutics Inc had received a complete response letter (CRL) from the USFDA which stated that the regulator has determined that it cannot approve the application for IV tramadol in its present form.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3p2lex5
via IFTTT
0 comments:
Post a Comment